MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
RDHL - Redhill Biopharma
$3.00
0.15(5.26%)6:00:01 PM 11/26/2021
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, with a planned Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), a SK2 selective inhibitor targeting various indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and in Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, a Phase 2-stage serine protease inhibitor for cancer and inflammatory gastrointestinal diseases, and is also being evaluated for COVID-19; and RHB-106, an encapsulated bowel preparation. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Summary:

  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
Stock Statistics
MarketCap139.1M
PE Ratio
PEG Ratio
P/B5.6
P/S (ttm)3.9
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %0%
Held by Institutions %25%
1 Day Vol Adjusted Return0.8
1 Month Vol Adjusted Return-6.5
3 Month Vol Adjusted Return-8.3
6 Month Vol Adjusted Return-7.9
20 Days SMA Price ZScore-1.4
50 Days SMA Price ZScore-2.3
12 -26 Days PPO-15.5
1 Month Average Short Volume Ratio40.8
1 Day Volume Change ZScore-0.3
1 Month Daily Vol6.9
Related Topics
Peers

Stock news

    11/24/2021RDHL
    RedHill Biopharma to Host Third Quarter 2021 Financial Results and Operational Highlights Webcast on November 30, 2021

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its third quarter 2021 financial results and operational highlights on Tuesday, November 30, 2021.

    11/23/2021RDHL
    RedHill Biopharma Announces Closing of $15.5 Million Public Offering of American Depositary Shares

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of the previously announced underwritten public offering of approximately 4.7 million American Depositary Shares ("ADSs") for gross proceeds of approximately $15.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by RedHill. Each ADS represents ten ordinary shares, par value NIS 0.01 per share, of

    11/19/2021RDHL
    Mid-Afternoon Market Update: Dow Falls 200 Points; Connect Biopharma Shares Tumble

    Toward the end of trading Friday, the Dow traded down 0.58% to 35,664.58 while the NASDAQ rose 0.53% to 16,078.19. The S&P also rose, gaining 0.05% to 4,706.69. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 48,398,450 cases with around 789,150 deaths. India confirmed a total of at least 34,489,620 cases and 465,080 deaths, while Brazil reported over 21,989,960 COVID-19 cases with 612,170 deaths. In total, there were at least 256,532,940 cases

    11/19/2021RDHL
    Mid-Day Market Update: Crude Oil Down Over 4%; UWM Holdings Shares Surge

    Midway through trading Friday, the Dow traded down 0.62% to 35,648.81 while the NASDAQ rose 0.53% to 16,078.23. The S&P also fell, dropping 0.01% to 4,704.35. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 48,398,450 cases with around 789,150 deaths. India confirmed a total of at least 34,489,620 cases and 465,080 deaths, while Brazil reported over 21,989,960 COVID-19 cases with 612,170 deaths. In total, there were at least 256,532,940 cases of

    11/19/2021RDHL
    RedHill Biopharma Announces Pricing of $15.5 Million Public Offering of American Depositary Shares

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the pricing of an underwritten public offering of 4.7 million American Depositary Shares ("ADSs") for gross proceeds of $15.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by RedHill. Each ADS represents ten ordinary shares, par value NIS 0.01 per share, of the Company. All of the ADSs are being offered by

    11/18/2021RDHL
    RedHill Biopharma Announces Underwritten Public Offering of American Depositary Shares

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced an underwritten public offering of American Depositary Shares ("ADSs"). Each ADS represents ten ordinary shares, par value NIS 0.01 per share, of the Company. All of the ADSs to be sold in the offering will be offered by RedHill. RedHill has granted the underwriter a 30-day option to purchase up to an additional 15 percent of the number of ADSs offered in the public offering

    11/16/2021RDHL
    When Can We Expect A Profit From RedHill Biopharma Ltd. (NASDAQ:RDHL)?

    RedHill Biopharma Ltd. ( NASDAQ:RDHL ) is possibly approaching a major achievement in its business, so we would like to...

    11/15/2021RDHL
    RedHill Biopharma Ltd Announces RedHill: LPI in Part A of RHB-107 P2/3 COVID Study

    , EU, UK and other territories, ahead of planned regulatory adviceTEL AVIV, ISRAEL and RALEIGH, NC / ACCESSWIRE / November 15, 2021 / RedHill Biopharma Ltd. (Nasdaq:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the last patient has been enrolled in Part A of the Phase 2/3 study with novel, once-daily, orally-administered pill RHB-107 (upamostat)[1] for non-hospitalized patients with symptomatic COVID-19.